Hormonal
Gut microbiota composition directly influences host glycemic control and insulin sensitivity through mechanisms including incretin secretion, short-chain fatty acid (SCFA) production, and bile acid metabolism.
Your gut bacteria play a key role in how your body handles sugar. Eating non-digestible carbohydrates (like inulin and oligofructose) can feed beneficial bacteria that produce short-chain fatty acids and stimulate hormones (GLP-1) that improve insulin response. This suggests that dietary fiber is not just for digestion but is a metabolic tool for glycemic control.
We will examine key biological molecular mechanisms underlying the impact of gut microbiota on host glycemic control including: incretin secretion, short-chain fatty acid production, bile acid metabolism, and adipose tissue regulation.
Why this rating
High-quality review summarizing multiple preclinical and clinical studies, though specific human intervention data is mixed.
Source
Impact of Gut Microbiota on Host Glycemic Control
Céline Gérard et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00029
More from this paper
- Prebiotic supplementation with non-digestible carbohydrates (e.g., oligofructose, inulin) improves glucose tolerance and insulin response by increasing GLP-1 secretion and SCFA production.Good
- Antidiabetic drugs like metformin and liraglutide exert part of their beneficial effects by modifying gut microbiota composition, specifically by increasing the abundance of Akkermansia muciniphila.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →